The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Open accessAbstract
The systematic translation of cancer genomic data into knowledge of tumour biology and therapeutic possibilities remains challenging. Such efforts should be greatly aided by robust preclinical model systems that reflect the genomic diversity of human cancers and for which detailed genetic and pharmacological annotation is available. Here we describe the Cancer Cell Line Encyclopedia (CCLE): a compilation of gene expression, chromosomal copy number and massively parallel sequencing data from 947 human cancer cell lines. When coupled with pharmacological profiles for 24 anticancer drugs across 479 of the cell lines, this collection allowed identification of genetic, lineage, and gene-expression-based predictors of drug sensitivity. In addition to known predictors, we found that plasma cell lineage correlated with sensitivity to IGF1 receptor inhibitors; AHR expression was associated with MEK inhibitor efficacy in NRAS-mutant lines; and SLFN11 expression predicted sensitivity to topoisomerase inhibitors. Together, our results indicate that large, annotated cell-line collections may help to enable preclinical stratification schemata for anticancer agents. The generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of 'personalized' therapeutic regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The CCLE dataset has previously been used to identify biomarkers for drug resistance and susceptibility (Barretina et al., 2012).”
From Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model (2018) · cites this paper as Barretina et al., 2012
Experimental — accuracy not yet measuredIn the citing paper
“JDQ443 antiproliferative activity was assessed by a high-throughput cell viability assay in a large panel of KRASG12C-mutated (N = 17) and non–G12C-mutated (N = 225) cell lines from the Cancer Cell Line Encyclopedia (29). JDQ443 demonstrated potent antiproliferative activity selectively toward the KRASG12C-mutated lines (Fig. 2A and B).”
In the citing paper
“However, large-scale drug sensitivity studies using the MEK and ERK inhibitors did not reveal the same degree of selectivity in KRAS mutant cells (69, 70) (Figure 4).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [69]
In the citing paper
“Large-scale efforts aimed at linking tumor genomic alterations with sensitivity to cytotoxic and targeted therapies have uncovered a wealth of pharmacogenomic interactions in NSCLC and other cancer types149–152.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [151]
In the citing paper
“interrogation of the expression data from the cancer cell line encyclopedia20 (CCLE) database revealed that classical SCLC cell lines have significantly reduced levels of EGFR mRNA compared with adenocarcinoma cell lines”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [20]
In the citing paper
“Other expression datasets integrated into the latest version are the Cancer Cell Line Encyclopedia (16) and cell perturbation expression data from the Library of Integrated Network-Based Cellular Signatures (17).”
From TCRD and pharos 2021: mining the human proteome for disease biology (2021) · cites this paper as [16]
In the citing paper
“The Passport model name is accompanied by synonyms and most importantly unique identifiers utilized by established resources such as Research Resource Identifiers (RRID) (19), the Catalogue of Somatic Mutations in Cancer (COSMIC) (20) and CCLE (6) to aid data integration and alignment.”
From Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models (2019) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppé, J., Tong, F. K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,224
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Self-citationDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Self-citationBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326
Self-citationAn Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183
High-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., Debiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 978
Self-citation
Cited by
Sorted by citations
Items 401–500 of 1,107
Deep learning for drug response prediction in cancer
Baptista, D., Ferreira, P. G., & Rocha, M. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz171 · Cited by 243
TumorFusions: an integrative resource for cancer-associated transcript fusions
Hu, X., Wang, Q., Tang, M., Barthel, F. P., Amin, S. B., Yoshihara, K., Lang, F., Martínez-Ledesma, E., Lee, S. H., Zheng, S., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1018 · Cited by 238
A microfluidics platform for combinatorial drug screening on cancer biopsies
Eduati, F., Utharala, R., Madhavan, D., Neumann, U. P., Longerich, T., Cramer, T., Saez-Rodriguez, J., & Merten, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-04919-w · Cited by 239
Raja, R. G., Kuziora, M. A., Brohawn, P. Z., Higgs, B. W., Gupta, A. K., Dennis, P. A., & Ranade, K. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0386 · Cited by 240
PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity
Kim, H., Kim, H., Feng, Y., Li, Y., Tamiya, H., Tocci, S., & Ronai, Z. A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz5683 · Cited by 247
Miotke, L. K., Lau, B. T., Rumma, R. T., & Ji, H. P. (2014) · Analytical Chemistry · doi:10.1021/ac403843j · Cited by 243
Macropinocytosis: A Metabolic Adaptation to Nutrient Stress in Cancer
Recouvreux, M. V., & Commisso, C. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00261 · Cited by 237
Feng, X., Arang, N., Rigiracciolo, D. C., Lee, J. S., Yeerna, H., Wang, Z., Lubrano, S., Kishore, A., Pachter, J. A., König, G. M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.009 · Cited by 237
Fallahi‐Sichani, M., Becker, V., Izar, B., Baker, G. J., Lin, J., Boswell, S. A., Shah, P., Rotem, A., Garraway, L. A., & Sorger, P. K. (2017) · Molecular Systems Biology · doi:10.15252/msb.20166796 · Cited by 237
Self-citationOncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA
Hosono, Y., Niknafs, Y. S., Prensner, J. R., Iyer, M. K., Dhanasekaran, S. M., Mehra, R., Pitchiaya, S., Tien, J. C.-Y., Escara-Wilke, J. F., Poliakov, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.11.040 · Cited by 238
Gong, X., Litchfield, L. M., Webster, Y., Chio, L.-C., Wong, S. S., Stewart, T. R., Dowless, M. S., Dempsey, J. A., Zeng, Y. A., Torres, R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.006 · Cited by 246
Hong, X., Roh, W., Sullivan, R. J., Wong, K. H. K., Wittner, B. S., Guo, H., Dubash, T. D., Sade-Feldman, M., Wesley, B., Horwitz, E. P., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1500 · Cited by 243
Self-citationMarti, P., Stein, C., Blumer, T., Abraham, Y., Dill, M. T., Pikiolek, M., Orsini, V., Jurisic, G., Megel, P., Makowska, Z., et al. (2015) · Hepatology · doi:10.1002/hep.27992 · Cited by 232
EMTome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures
Vasaikar, S. V., Deshmukh, A. P., den Hollander, P., Addanki, S., Kuburich, N. A., Kudaravalli, S., Joseph, R., Chang, J. T., Soundararajan, R., & Mani, S. A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01178-9 · Cited by 232
Inferring causal molecular networks: empirical assessment through a community-based effort
Hill, S. M., Heiser, L. M., Cokelaer, T., Unger, M., Nesser, N. K., Carlin, D. E., Zhang, Y., Sokolov, A., Paull, E., Wong, C., et al. (2016) · Nature Methods · doi:10.1038/nmeth.3773 · Cited by 232
ARID1A-mutated ovarian cancers depend on HDAC6 activity
Bitler, B. G., Wu, S., Park, P. H., Hai, Y., Aird, K. M., Wang, Y., Zhai, Y., Kossenkov, A. V., Vara-Ailor, A., Rauscher, F. J., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3582 · Cited by 232
Preclinical and clinical development of neoantigen vaccines
Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx681 · Cited by 237
Sack, L. M., Davoli, T., Li, M. Z., Li, Y., Xu, Q., Naxerova, K., Wooten, E. C., Bernardi, R. J., Martin, T. D., Chen, T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.037 · Cited by 225
Larsson, P., Engqvist, H., Biermann, J., Rönnerman, E. W., Forssell-Aronsson, E. B., Kovács, A., Karlsson, P., Helou, K., & Parris, T. Z. (2020) · Scientific Reports · doi:10.1038/s41598-020-62848-5 · Cited by 239
Biomarker-Guided Development of DNA Repair Inhibitors
Cleary, J. M., Aguirre, A. J., Shapiro, G. I., & D’Andrea, A. D. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.035 · Cited by 239
Targeting tumour-supportive cellular machineries in anticancer drug development
Dobbelstein, M., & Moll, U. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4201 · Cited by 233
Wu, D., Wang, D., Zhang, M. Q., & Gu, J. (2015) · BMC Genomics · doi:10.1186/s12864-015-2223-8 · Cited by 233
BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Barras, D., Missiaglia, E., Wirapati, P., Sieber, O. M., Jorissen, R. N., Love, C., Molloy, P. L., Jones, I. T., McLaughlin, S., Gibbs, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0140 · Cited by 231
Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer
Madak, J. T., Bankhead, A., Cuthbertson, C. R., Showalter, H. D., & Neamati, N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.10.012 · Cited by 230
MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors
Birsoy, K., Wang, T., Possemato, R., Yilmaz, Ö. H., Koch, C. E., Chen, W. W., Hutchins, A., Gültekin, Y., Peterson, T. R., Carette, J. E., et al. (2012) · Nature Genetics · doi:10.1038/ng.2471 · Cited by 232
Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy
Eng, C. H., Wang, Z., Tkach, D., Toral‐Barza, L., Ugwonali, S., Liu, S., Fitzgerald, S., George, E., Frias, E., Cochran, N. R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515617113 · Cited by 229
Patient-derived micro-organospheres enable clinical precision oncology
Ding, S., Hsu, C., Wang, Z., Natesh, N. R., Millen, R., Negrete, M., Giroux, N., Rivera, G. O., Dohlman, A., Bose, S., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.04.006 · Cited by 228
Pan-cancer proteomic map of 949 human cell lines
Gonçalves, E., Poulos, R. C., Cai, Z., Barthorpe, S., Manda, S. S., Lucas, N., Beck, A., Bucio-Noble, D., Dausmann, M., Hall, C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.010 · Cited by 239
In vitro models of medulloblastoma: Choosing the right tool for the job
Ivanov, D. P., Coyle, B., Walker, D. A., & Grabowska, A. M. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2016.07.028 · Cited by 231
Stewart, C. A., Tong, P., Cardnell, R. J., Sen, T., Li, L., Gay, C. M., Masrorpour, F., Fan, Y. H., Bara, R. O., Feng, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15338 · Cited by 232
Synthetic lethality between CCNE1 amplification and loss of BRCA1
Etemadmoghadam, D., Weir, B. A., Au‐Yeung, G., Alsop, K., Mitchell, G., George, J., Australian Ovarian Cancer Study Group, Davis, S. J., D’Andrea, A. D., Simpson, K. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314302110 · Cited by 225
Caetano, M. S., Zhang, H., Cumpian, A. M., Gong, L., Ünver, N., Ostrin, E. J., Daliri, S., Chang, S. H., Ochoa, C. E., Hanash, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2840 · Cited by 228
Predicting drug response of tumors from integrated genomic profiles by deep neural networks
Chiu, Y., Chen, H.-I. H., Zhang, T., Zhang, S., Gorthi, A., Wang, L., Huang, Y., & Chen, Y. (2019) · BMC Medical Genomics · doi:10.1186/s12920-018-0460-9 · Cited by 232
Self-citationThe Proteomic Landscape of Triple-Negative Breast Cancer
Lawrence, R., Perez, E. M., Hernández, D., Miller, C. P., Haas, K. M., Irie, H. Y., Lee, S., Blau, C. A., & Villén, J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.050 · Cited by 225
Schmidt, T., Samaras, P., Frejno, M., Gessulat, S., Barnert, M., Kienegger, H., Krcmar, H., Schlegl, J., Ehrlich, H., Aiche, S., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1029 · Cited by 228
Cancer Vulnerabilities Unveiled by Genomic Loss
Nijhawan, D., Zack, T. I., Ren, Y., Strickland, M. R., Lamothe, R. C., Schumacher, S. E., Tsherniak, A., Besche, H. C., Rosenbluh, J., Shehata, S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.07.023 · Cited by 225
Self-citationTACO produces robust multisample transcriptome assemblies from RNA-seq
Niknafs, Y. S., Pandian, B., Iyer, H. K., Chinnaiyan, A. M., & Iyer, M. K. (2016) · Nature Methods · doi:10.1038/nmeth.4078 · Cited by 219
Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer
Ferrara, R., Auger, N., Auclin, É., & Besse, B. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.021 · Cited by 228
A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer
Peng, X., Xu, X., Wang, Y., Hawke, D. H., Yu, S., Han, L., Zhou, Z., Mojumdar, K., Jeong, K. J., Labrie, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.026 · Cited by 227
Artificial intelligence, machine learning, and drug repurposing in cancer
Tanoli, Z., Vähä-Koskela, M. J. V., & Aittokallio, T. A. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1883585 · Cited by 229
Dihydropyrimidine Accumulation Is Required for the Epithelial-Mesenchymal Transition
Shaul, Y. D., Freinkman, E., Comb, W. C., Cantor, J. R., Tam, W. L., Thiru, P., Kim, D., Kanarek, N., Pacold, M. E., Chen, W. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.032 · Cited by 223
Noll, E. M., Eisen, C., Stenzinger, A., Espinet, E., Muckenhuber, A., Klein, C., Vogel, V., Klaus, B., Nadler, W. M., Roesli, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4038 · Cited by 228
Genomic evolution of cancer models: perils and opportunities
Ben‐David, U., Beroukhim, R., & Golub, T. R. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0095-3 · Cited by 234
Self-citationFunctional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
Gechijian, L. N., Buckley, D. L., Lawlor, M. A., Reyes, J. M., Paulk, J., Ott, C. J., Winter, G. E., Erb, M. A., Scott, T. G., Xu, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0010-y · Cited by 222
Diagnostic classification of cancers using extreme gradient boosting algorithm and multi-omics data
Ma, B., Meng, F., Ge, Y., Yan, H., Chai, B., & Song, F. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.103761 · Cited by 221
Barèche, Y., Buisseret, L., Gruosso, T., Girard, E., Venet, D., Dupont, F., Desmedt, C., Larsimont, D., Park, M., Rothé, F., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz208 · Cited by 221
Ji, Z., He, L., Regev, A., & Struhl, K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821068116 · Cited by 220
Pathways and therapeutic targets in melanoma
Shtivelman, E., Davies, M. A., Hwu, P., Yang, J. C.-H., Lotem, M., Oren, M., Flaherty, K. T., & Fisher, D. E. (2014) · Oncotarget · doi:10.18632/oncotarget.1892 · Cited by 226
Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets
Chen, B., Ma, L., Paik, H., Sirota, M., Wei, W., Chua, M., So, S. K., & Butte, A. J. (2017) · Nature Communications · doi:10.1038/ncomms16022 · Cited by 220
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Raoof, S., Mulford, I. J., Frisco-Cabanos, H., Nangia, V., Timonina, D., Labrot, E., Hafeez, N., Bilton, S. J., Drier, Y., Ji, F., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0887-2 · Cited by 216
Self-citationXiao, Z., Han, L., Lee, H., Zhuang, L., Zhang, Y., Baddour, J., Nagrath, D., Wood, C. G., Gu, J. H., Wu, X., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00902-z · Cited by 216
Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity
Li, L., Knútsdóttir, H., Hui, K., Weiss, M. J., He, J. P., Philosophe, B., Cameron, A. M., Wolfgang, C. L., Pawlik, T. M., Ghiaur, G., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.121490 · Cited by 216
A genome-wide positioning systems network algorithm for in silico drug repurposing
Cheng, F., Lu, W., Liu, C., Fang, J., Hou, Y., Handy, D. E., Wang, R., Zhao, Y., Yang, Y., Huang, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10744-6 · Cited by 215
Tight junction proteins: From barrier to tumorigenesis
Runkle, E. A., & Mu, D. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.038 · Cited by 216
Zhang, Y., Zheng, D., Zhou, T., Song, H., Hulsurkar, M. M., Su, N., Liu, Y., Wang, Z., Shao, L., Ittmann, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06177-2 · Cited by 219
In vivo tumor growth of high-grade serous ovarian cancer cell lines
Mitra, A. K., Davis, D. A., Tomar, S., Roy, L., Main, H. G., Xie, J., Lantvit, D. D., Cárdenas, H., Fang, F., Liu, Y., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.05.040 · Cited by 214
Kong, J., Lee, H., Kim, D., Han, S. K., Ha, D., Shin, K., & Kim, S. (2020) · Nature Communications · doi:10.1038/s41467-020-19313-8 · Cited by 225
Self-citationDesign and analysis of CRISPR–Cas experiments
Hanna, R. E., & Doench, J. G. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0490-7 · Cited by 216
Coscia, F., Watters, K. M., Curtis, M., Eckert, M. A., Chiang, C. Y., Tyanova, S., MONTAG, A. G., Lastra, R. R., Lengyel, E. R., & Mann, M. (2016) · Nature Communications · doi:10.1038/ncomms12645 · Cited by 210
Tsimberidou, A. M., Wen, S., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S. A., Naing, A., Jankú, F., Aldape, K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0603 · Cited by 210
Alvarez, M. J., Subramaniam, P. S., Tang, L. H., Grunn, A., Aburi, M., Rieckhof, G., Komissarova, E. V., Hagan, E. A., Bodei, L., Clemons, P. A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0138-4 · Cited by 210
HER2 aberrations in cancer: Implications for therapy
Yan, M., Parker, B. A., Schwab, R. B., & Kurzrock, R. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.008 · Cited by 212
Methylation-dependent regulation of HIF-1α stability restricts retinal and tumour angiogenesis
Kim, Y., Nam, H. J., Lee, J., Park, D. Y., Kim, C., Yu, Y. S., Kim, D., Park, S. W., Bhin, J., Hwang, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms10347 · Cited by 218
Braun, C. J., Stanciu, M., Boutz, P. L., Patterson, J. C., Calligaris, D., Higuchi, F., Neupane, R., Fenoglio, S., Cahill, D. P., Wakimoto, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.018 · Cited by 207
Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer
Barger, C. J., Branick, C., Chee, L., & Karpf, A. R. (2019) · Cancers · doi:10.3390/cancers11020251 · Cited by 209
Graph Convolutional Networks for Drug Response Prediction
Nguyen, T., Nguyen, G. T. T., Nguyen, T., & Le, D. (2021) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2021.3060430 · Cited by 215
Predicting Anticancer Drug Responses Using a Dual-Layer Integrated Cell Line-Drug Network Model
Zhang, N., Wang, H., Fang, Y., Wang, J., Zheng, X., & Liu, X. S. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004498 · Cited by 208
Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer
Jiang, G., Zhang, S., Yazdanparast, A., Li, M., Pawar, A., Liu, Y., Inavolu, S. M., & Cheng, L. (2016) · BMC Genomics · doi:10.1186/s12864-016-2911-z · Cited by 210
Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays
Li, J., Zhao, W., Akbani, R., Liu, W., Ju, Z., Ling, S., Vellano, C. P., Roebuck, P. L., Yu, Q., Eterovic, A. K., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.005 · Cited by 206
Ali, M., & Aittokallio, T. A. (2018) · Biophysical Reviews · doi:10.1007/s12551-018-0446-z · Cited by 213
Luna, A., Elloumi, F., Varma, S., Wang, Y., Rajapakse, V. N., Aladjem, M. I., Robert, J., Sander, C., Pommier, Y. G., & Reinhold, W. C. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa968 · Cited by 212
Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors
Roudko, V., Bozkus, C. C., Orfanelli, T., McClain, C. B., Carr, C. E., O’Donnell, T. J., Chakraborty, L., Samstein, R. M., Huang, K., Blank, S. V., et al. (2020) · Cell · doi:10.1016/j.cell.2020.11.004 · Cited by 219
An omics perspective on drug target discovery platforms
Paananen, J., & Fortino, V. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz122 · Cited by 216
Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin
Stanton, B. Z., Hodges, H. C., Calarco, J. P., Braun, S. M. G., Ku, W. L., Kadoch, C., Zhao, K., & Crabtree, G. R. (2016) · Nature Genetics · doi:10.1038/ng.3735 · Cited by 215
Gayle, S., Landrette, S. F., Beeharry, N., Conrad, C., Hernandez, M., Beckett, P., Ferguson, S. M., Mandelkern, T. F., Zheng, M., Xu, T., et al. (2017) · Blood · doi:10.1182/blood-2016-09-736892 · Cited by 205
Young, R. J., Waldeck, K., Martin, C., Foo, J. H., Cameron, D. P., Kirby, L., Do, H., Mitchell, C., Cullinane, C. M., Liu, W. J., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12228 · Cited by 206
The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
Maroun, C. R., & Rowlands, T. M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.014 · Cited by 206
Martı́n, D., Abba, M. C., Molinolo, A., Vitale-Cross, L. A., Wang, Z., Zaida, M., Delic, N. C., Samuels, Y., Lyons, J. G., & Gutkind, J. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2417 · Cited by 206
Liu, Q., & Xie, L. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008653 · Cited by 205
MCART1/SLC25A51 is required for mitochondrial NAD transport
Kory, N., uit de Bos, J., van der Rijt, S., Jankovic, N., Güra, M., Arp, N., Pena, I. A., Prakash, G., Chan, S. H., Kunchok, T., et al. (2020) · Science Advances · doi:10.1126/sciadv.abe5310 · Cited by 205
NADPH Oxidases: A Perspective on Reactive Oxygen Species Production in Tumor Biology
Meitzler, J. L., Antony, S., Wu, Y., Juhasz, A. N., Liu, H., Jiang, G., Lu, J., Roy, K., & Doroshow, J. H. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5603 · Cited by 213
The recurrent architecture of tumour initiation, progression and drug sensitivity
Califano, A., & Alvarez, M. J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.124 · Cited by 203
Massively parallel pooled screening reveals genomic determinants of nanoparticle delivery
Boehnke, N., Straehla, J. P., Safford, H. C., Kocak, M., Rees, M. G., Ronan, M. M., Rosenberg, D., Adelmann, C. H., Chivukula, R. R., Nabar, N., et al. (2022) · Science · doi:10.1126/science.abm5551 · Cited by 204
A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma
Pozniak, J., Pedri, D., Landeloos, E., Van Herck, Y., Antoranz, A., Vanwynsberghe, L., Nowosad, A., Roda, N., Makhzami, S., Bervoets, G., et al. (2024) · Cell · doi:10.1016/j.cell.2023.11.037 · Cited by 199
Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer
García‐Alonso, L., Iorio, F., Matchan, A., Fonseca, N. A., Jaaks, P., Peat, G., Pignatelli, M., Falcone, F., Benes, C. H., Dunham, I., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1679 · Cited by 199
Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy
Lee, J., Liu, Z., Sa, J. K., Shin, S. H., Wang, J., Bordyuh, M., Cho, H. J., Elliott, O., Chu, T., Choi, S. W., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0209-6 · Cited by 207
Self-citationA Pharmacogenomic Landscape in Human Liver Cancers
Qiu, Z., Li, H., Zhang, Z., Zhu, Z., He, S., Wang, X., Wang, P., Qin, J., Zhuang, L., Wang, W., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.07.001 · Cited by 204
Drugging PI3K in cancer: refining targets and therapeutic strategies
Yap, T. A., Bjerke, L. M., Clarke, P. A., & Workman, P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.016 · Cited by 206
The Role of Nuclear Receptor–Binding SET Domain Family Histone Lysine Methyltransferases in CancerPreprint
Bennett, R. L., Swaroop, A., Troche, C., & Licht, J. D. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026708 · Cited by 203
Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome
You, S., Knudsen, B. S., Erho, N., Alshalalfa, M., Takhar, M. M., Ashab, H. A.-D., Davicioni, E., Karnes, R. J., Klein, E. A., Den, R. B., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0902 · Cited by 209
Quantifying drug combination synergy along potency and efficacy axes
Meyer, C. T., Wooten, D. J., Paudel, B. B., Bauer, J., Hardeman, K. N., Westover, D., Lovly, C. M., Harris, L. A., Tyson, D. R., & Quaranta, V. (2019) · Cell Systems · doi:10.1016/j.cels.2019.01.003 · Cited by 202
Jabs, J., Zickgraf, F. M., Park, J., Wagner, S., Jiang, X., Jechow, K., Kleinheinz, K., Toprak, U. H., Schneider, M. A., Meister, M. A., et al. (2017) · Molecular Systems Biology · doi:10.15252/msb.20177697 · Cited by 209
Review of processing and analysis methods for DNA methylation array data
Wilhelm-Benartzi, C. S., Koestler, D. C., Karagas, M. R., Flanagan, J. M., Christensen, B. C., Kelsey, K. T., Marsit, C. J., Houseman, E. A., & Brown, R. E. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.496 · Cited by 210
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma
Hedberg, M. L., Goh, G., Chiosea, S. I., Bauman, J. E., Freilino, M. L., Zeng, Y., Wang, L., Diergaarde, B. B., Gooding, W. E., Lui, V. W. Y., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82066 · Cited by 208
Self-citationSubCellBarCode: Proteome-wide Mapping of Protein Localization and Relocalization
Orre, L. M., Vesterlund, M., Pan, Y., Arslan, T., Zhu, Y., Fernandez-Woodbridge, A., Frings, O., Fredlund, E., & Lehtiö, J. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.11.035 · Cited by 201
Daher, B., Parks, S. K., Durivault, J., Cormerais, Y., Baidarjad, H., Tambutté, É., Pouysségur, J., & Vučetić, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3855 · Cited by 208
Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine
Wang, W., Cui, J., Ma, H., Lü, W., & Huang, J. Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684961 · Cited by 203
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinomaPreprint
Huang, C., Lujambio, A., Zuber, J. A., Tschaharganeh, D. F., Doran, M. G., Evans, M. J., Kitzing, T. M., Zhu, N., de Stanchina, E., Sawyers, C. L., et al. (2014) · Genes & Development · doi:10.1101/gad.244368.114 · Cited by 204
UCSCXenaShiny: an R/CRAN package for interactive analysis of UCSC Xena data
Wang, S., Xiong, Y., Zhao, L., Gu, K., Li, Y., Zhao, F., Li, J., Wang, M., Wang, H., Tao, Z., et al. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab561 · Cited by 199
Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing eventsPreprint
Liu, J., Lee, W., Jiang, Z., Chen, Z., Jhunjhunwala, S., Haverty, P. M., Gnad, F., Guan, Y., Gilbert, H., Stinson, J., et al. (2012) · Genome Research · doi:10.1101/gr.140988.112 · Cited by 208
Metadata
- Authors
- Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., Reddy, A., Liu, M., Murray, L., Berger, M. F., Monahan, J. E., Morais, P., Meltzer, J., Korejwa, A., Jané-Valbuena, J., Mapa, F. A., Thibault, J., Bric-Furlong, E., Raman, P., Shipway, A., Engels, I. H., Cheng, J., Yu, G. K., Yu, J., Aspesi, P., de Silva, M., Jagtap, K., Jones, M. D., Wang, L., Hatton, C., Palescandolo, E., Gupta, S., Mahan, S., Sougnez, C., Onofrio, R. C., Liefeld, T., MacConaill, L., Winckler, W., Reich, M., Li, N., Mesirov, J. P., Gabriel, S. B., Getz, G., Ardlie, K., Chan, V., Myer, V. E., Weber, B. L., Porter, J., Warmuth, M., Finan, P., Harris, J. L., Meyerson, M., Golub, T. R., Morrissey, M. P., Sellers, W. R., Schlegel, R., & Garraway, L. A.
- Affiliations
- Broad Institute (US)
- Genomics Institute of the Novartis Research Foundation (US)
- Harvard University (US)
- Corresponding author
- Schlegel, Robert
- Garraway, Levi A.
- ORCID
- Barretina, Jordi
- Stransky, Nicolas
- Venkatesan, Kavitha
- Wilson, Christopher J.
- Lehár, Joseph
- Kryukov, Gregory V.
- Sonkin, Dmitriy
- Reddy, Anupama
- Liu, Manway
- Murray, Lauren
- Berger, Michael F.
- Monahan, John E.
- Mapa, Felipa A.
- Raman, Pichai
- Yu, Guoying K.
- Yu, Jianjun
- Aspesi, Peter
- Jones, Michael D.
- Wang, Li
- Gupta, Supriya
- Liefeld, Ted
- MacConaill, Laura
- Winckler, Wendy
- Reich, Michael
- Li, Nanxin
- Mesirov, Jill P.
- Gabriel, Stacey B.
- Getz, Gad
- Ardlie, Kristin
- Chan, Vivien
- Myer, Vic E.
- Weber, Barbara L.
- Meyerson, Matthew
- Golub, Todd R.
- Sellers, William R.
- Garraway, Levi A.
- Venue
- Nature
- Published
- 2012-03-28
- Volume
- 483
- Issue
- 7391
- Pages
- 603-607
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3320027
- OpenAlex
- W2043398720
- Cited by
- 7,950
- References
- 28
- Citations by year
- 2026: 361 · 2025: 501 · 2024: 617 · 2023: 719 · 2022: 723 · 2021: 839 · 2020: 682 · 2019: 687 · 2018: 628 · 2017: 500 · 2016: 516 · 2015: 436 · 2014: 348 · 2013: 283 · 2012: 103
- FWCI
- 124.24
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (DP2OD002750)
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (R33CA155554, R33CA126674)
- National Institute of General Medical Sciences (R01GM074024)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- Cancer Cell Line Encyclopedia, anticancer drug sensitivity, drug resistance, cancer cell lines, Ewing sarcoma, PARP inhibitors, SLFN11, topoisomerase inhibitors, MEK inhibitors, NRAS mutation, aryl hydrocarbon receptor, gene expression profiles, chromosomal copy number, predictive modeling, precision oncology
- MeSH terms
- Antineoplastic Agents, Chromosomes, Human, Clinical Trials as Topic, Drug Screening Assays, Antitumor, Encyclopedias as Topic, Humans, Models, Biological, Neoplasms, Pharmacogenetics, Plasma Cells, Genes, ras, Genome, Human, Gene Expression Regulation, Neoplastic, Databases, Factual, Sequence Analysis, DNA, Receptor, IGF Type 1, Receptors, Aryl Hydrocarbon, Cell Lineage, Gene Expression Profiling, Mitogen-Activated Protein Kinase Kinases, Genomics, Cell Line, Tumor, Precision Medicine, Topoisomerase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
